top of page

Chikungunya
Real-Time PCR Kit

Chikungunya Real-Time PCR Detection Kit is a multiplex, TaqMan probe based qualitative assay for the specific detection of Chikungunya virus from human clinical samples, which includes plasma, serum and whole Blood. Primers and probes are designed to specifically detect RNA of non structural protein (nsp) coding gene, along with an internal control.

SKU

  • 100 Rxns : NCRD23059

  •  50 Rxns : NCRD23059_01

  • 20 Rxns : NCRD23059_02

Chikungunya Real-Time PCR Kit (1).png
Features & Benefits: 

  • Multiplex, TaqMan probe-based qualitative assay designed to detect viral RNA in human clinical samples, including whole blood, plasma, and serum. ​

  • Compatibility: The kit is an open-platform solution compatible with four-channel RT-PCR machines.

  • Efficiency: The PCR run time is 60 minutes.

  • Targets: The assay targets non-structural protein (nsp) coding genes for viral detection, alongside an internal control using Beta Actin.

  • Lineage Coverage: It is designed to detect five genetic lineages: Asian, West African, and three Eastern Central South African (ECSA 1, ECSA 2, and ECSA 3).

  • Reporter Dyes: The Chikungunya target uses the HEX dye, while the internal control uses the Texas Red dye.

Storage & Precautions

  • Recommended Storage: -20°C

  • For Professional Use only.

  • Read user manual

Clinical Relevance

Primarily transmitted by Aedes aegypti and Aedes albopictus mosquitoes, the Chikungunya virus (CHIKV) is the causative agent of Chikungunya fever, a disease marked by febrile illness, excruciating joint and muscular pain, headache, nausea, lethargy, and rash. Three genotypes of the disease—West African, East/Central/South African (ECSA), and Asian were first recorded in Tanzania in 1952. Another distinct sublineage arising from the ECSA lineage during the Indian Ocean outbreak is called the Indian Ocean lineage (IOL). CHIKV isolates from the 2013 Caribbean also form a novel American sublineage within the Asian lineage (Asian/American). Worldwide, millions of people have been afflicted by major chikungunya outbreaks in Asia, Africa, Europe, and the Americas. In 2024, and as of 31 May, approximately 32,000 CHIKVD cases
and over 120 deaths have been reported worldwide. A total of 19 countries reported CHIKVD cases from the Americas (12), Asia (6), and Africa (1). Although chikungunya seldom results in death, the crippling joint pain it causes can last for
months, negatively affecting quality of life and placing a strain on healthcare systems. Clinical assessment and laboratory testing, such as Real-time PCR and serological assays are used to identify viral RNA or antibodies.

bottom of page